Review
Cell Biology
Stefano A. Pileri, Claudio Tripodo, Federica Melle, Giovanna Motta, Valentina Tabanelli, Stefano Fiori, Maria Carmela Vegliante, Saveria Mazzara, Sabino Ciavarella, Enrico Derenzini
Summary: Diffuse large B-cell lymphoma is the most common form of lymphoid malignancy globally, with a classification including a common form and a series of rare variants. Recent studies have focused on identifying prognostic/predictive factors for the use of tailored therapies in patients.
Article
Medicine, General & Internal
Andreea Nicoleta Serbanica, Delia Codruta Popa, Constantin Caruntu, Sergiu Pasca, Cristian Scheau, Ionut Vlad Serbanica, Raluca Suciu, Valeria Tica, Elisa Busescu, Luminita Nicoleta Cima, Cerasela Jardan, Mihaela Dragomir, Daniel Coriu, Andrei Colita, Anca Colita
Summary: This retrospective study evaluated the expression of CD20 in 114 patients with B-cell precursor acute lymphoblastic leukemia (B-ALL), and found that CD20 expression was associated with disease evolution. The results suggest that CD20 expression level is an important factor in the assessment and treatment of pediatric patients with B-ALL.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Fedor Berditchevski, Eanna Fennell, Paul G. Murray
Summary: Induced waves of calcium fluxes play a crucial role in the differentiation and maturation of B-cells, while dysregulation of calcium fluxes may lead to B-cell lymphomagenesis. Several cytotoxic drugs target calcium-dependent pathways for lymphoma treatment.
Review
Immunology
Hao Xu, Ningwen Li, Gaoxiang Wang, Yang Cao
Summary: Genetically modified T-cell immunotherapies, specifically CD19-directed chimeric antigen receptor (CAR)-T therapy, show impressive efficacy in refractory/relapsed B-cell non-Hodgkin lymphoma patients. However, resistance and relapse following CAR-T therapy are significant concerns. Efforts have been made to identify biomarkers that can predict responses and outcomes after CAR-T immunotherapy and to understand the mechanisms of treatment failure.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Faustino Julian Suarez-Sanchez, Paloma Lequerica-Fernandez, Juan Pablo Rodrigo, Francisco Hermida-Prado, Julian Suarez-Canto, Tania Rodriguez-Santamarta, Francisco Dominguez-Iglesias, Juana M. Garcia-Pedrero, Juan Carlos de Vicente
Summary: The study found that infiltrating CD20(+) B lymphocytes in oral squamous cell carcinoma (OSCC) are related to other immune subtypes and clinical prognosis, suggesting they may serve as an independent good prognostic factor in OSCC.
Article
Hematology
Maurice Reimann, Jens Schrezenmeier, Paulina Richter-Pechanska, Anna Dolnik, Timon Pablo Hick, Kolja Schleich, Xiurong Cai, Dorothy N. Y. Fan, Philipp Lohneis, Sven Masswig, Sophy Denker, Antonia Busse, Gero Knittel, Ruth Flumann, Dorothee Childs, Liam Childs, Ana-Maria Gaetjens-Sanchez, Lars Bullinger, Andreas Rosenwald, Hans Christian Reinhardt, Clemens A. Schmitt
Summary: The aberrant B-cell receptor/NF-kB signaling is a hallmark feature of B-cell non-Hodgkin lymphomas, especially in diffuse large B-cell lymphoma (DLBCL). Mutations in CD79B, CARD11, NFKBIZ, and MyD88 deregulate NF-kB but their differential impact on lymphoma development remains to be fully understood. Further investigation into primary mouse lymphomas revealed mutant-specific dependencies that were therapeutically exploitable by anti-programmed cell death 1 check-point blockade, providing insights into potential personalized treatment strategies for human DLBCL subsets.
Article
Oncology
Marco De Martino, Pedro Nicolau-Neto, Luis Felipe Ribeiro Pinto, Alexandra Traverse-Glehen, Emmanuel Bachy, Vincenzo Gigantino, Rossella De Cecio, Francesco Bertoni, Paolo Chieffi, Alfredo Fusco, Francesco Esposito
Summary: The study found a significant correlation between HMGA1 and EZH2 expression in human lymphomas, where HMGA1 was able to bind the EZH2 promoter and induce its activity. Silencing HMGA1 expression resulted in decreased EZH2 levels, leading to reduced proliferation and migration rates of human lymphoma cell lines. These findings identify HMGA1 as an activator of EZH2, suggesting a novel molecular mechanism contributing to EZH2 overexpression in human malignancies and a synergism between the two proteins in cancer progression.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Chemistry, Medicinal
Yunpeng Zhao, Yongzhi Shu, Jun Lin, Zhendong Chen, Qiong Xie, Yanning Bao, Lixue Lu, Nannan Sun, Yonghui Wang
Summary: BTK is a key drug target for B-cell malignancies, and the covalent BTK inhibitors face drug resistance issues. PROTAC technology can increase sensitivity to drug-resistant targets, and ARQ531 as a non-covalent BTK inhibitor may serve as an ideal warhead for PROTACs.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Immunology
Alice Turdo, Miriam Gaggianesi, Caterina D'Accardo, Gaetana Porcelli, Sebastiano Di Bella, Dario Cricchio, Irene Pillitteri, Rossana Porcasi, Melania Lo Iacono, Francesco Verona, Chiara Modica, Narges Roozafzay, Ada Maria Florena, Giorgio Stassi, Salvatrice Mancuso, Matilde Todaro
Summary: This study identified a gene signature that can predict the response to R-CHOP therapy in DLBCL patients. These findings aid in the stratification of responder and non-responder patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Zhiwei Ang, Luca Paruzzo, Katharina E. Hayer, Carolin Schmidt, Manuel Torres Diz, Feng Xu, Urvi Zankharia, Yunlin Zhang, Samantha Soldan, Sisi Zheng, Catherine D. Falkenstein, Joseph P. Loftus, Scarlett Y. Yang, Mukta Asnani, Patricia King Sainos, Vinodh Pillai, Emeline Chong, Marilyn M. Li, Sarah K. Tasian, Yoseph Barash, Paul M. Lieberman, Marco Ruella, Stephen J. Schuster, Andrei Thomas-Tikhonenko
Summary: Skipping of coding exons in CD19 and CD22 genes compromises immunotherapy response in B-cell malignancies. This study demonstrates that CD20 gene (MS4A1) also produces multiple mRNA isoforms with distinct untranslated regions. Modulating CD20 isoforms enhances CD20 expression and antibody-mediated cytotoxicity, potentially overcoming immunotherapy resistance.
Article
Oncology
Alyxzandria M. Gaydosik, Connor J. Stonesifer, Alexandra E. Khaleel, Larisa J. Geskin, Patrizia Fuschiotti
Summary: This study used single-cell methods to investigate the transcriptional profiles of malignant T-cell clones and reactive T lymphocytes in mycosis fungoides/Sezary syndrome patient samples. The study found that there are several expanded clonotypes in the skin and blood of individual patients, as well as upregulation of common pathways associated with cancer cell metabolism, cell-cycle regulation, de novo nucleotide biosynthesis, and invasion. These findings provide new insights into the pathogenesis of mycosis fungoides/Sezary syndrome and potential targets for personalized therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Nuria Profitos-Peleja, Juliana Carvalho Santos, Ana Marin-Niebla, Gael Roue, Marcelo Lima Ribeiro
Summary: Dysregulated BCR signaling is a crucial factor in the survival of B-NHL tumors, and BCR-targeted therapies provide alternative treatment options. However, durable responses to these drugs are often not achieved. This review discusses the role of BCR signaling in B-NHLs, the mechanisms of BCR-targeted therapies, and the development of new treatment strategies.
Review
Cell Biology
Wei Xiao, Juan Li, June Hu, Lingzhi Wang, Jiang-Rong Huang, Gautam Sethi, Zhaowu Ma
Summary: circRNAs, a type of non-coding RNA characterized by high abundance and cell-specific expression, play crucial roles in regulating the cell cycle and biological processes through various mechanisms of gene expression regulation.
CELL PROLIFERATION
(2021)
Article
Biochemistry & Molecular Biology
Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Lara Ruoff, Christian Martin Seitz, Patrick Schlegel
Summary: CD19CAR T cells show promising results in treating relapsed and refractory aggressive B-lineage cancers. The AdCAR technology allows multitargeting and flexibility in adapting to different antigen profiles, increasing treatment effectiveness and overcoming antigen immune escape.
Article
Dermatology
R. Varaljai, S. Elouali, S. S. Lueong, K. Wistuba-Hamprecht, T. Seremet, J. T. Siveke, J. C. Becker, A. Sucker, A. Paschen, P. A. Horn, B. Neyns, B. Weide, D. Schadendorf, A. Roesch
Summary: This study demonstrates that high cfDNA concentration can serve as a biomarker for melanoma regardless of tumor genotype, providing information on tumor burden, risk of progression, and risk of death.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Spela Kos, Natasa Tesic, Urska Kamensek, Tanja Blagus, Maja Cemazar, Simona Kranjc, Jaka Lavrencak, Gregor Sersa
JOURNAL OF MEMBRANE BIOLOGY
(2015)
Article
Cell Biology
U. Klopcic, J. Lavrencak, G. Gasljevic, M. Bracko, Z. Pohar-Marinsek, V. Kloboves-Prevodnik
Correction
Biochemistry & Molecular Biology
Masa Bosnjak, Urska Kamensek, Gregor Sersa, Danijela Stolfa, Jaka Lavrencak, Maja Cemazar
JOURNAL OF MEMBRANE BIOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Masa Bosnjak, Urska Kamensek, Gregor Sersa, Danijela Stolfa, Jaka Lavrencak, Maja Cemazar
JOURNAL OF MEMBRANE BIOLOGY
(2018)
Article
Engineering, Biomedical
Sara Prijic, Lara Prosen, Maja Cemazar, Janez Scancar, Rok Romih, Jaka Lavrencak, Vladimir B. Bregar, Andrej Coer, Mojca Krzan, Andrej Znidarsic, Gregor Sersa
Article
Biochemistry & Molecular Biology
B. Markelc, G. Tevz, M. Cemazar, S. Kranjc, J. Lavrencak, B. Zegura, J. Teissie, G. Sersa
Article
Oncology
Mateja Horvat, Veronika Kloboves Prevodnik, Jaka Lavrencak, Barbara Jezersek Novakovic
Article
Multidisciplinary Sciences
Tanja Dolinsek, Bostjan Markelc, Gregor Sersa, Andrej Coer, Monika Stimac, Jaka Lavrencak, Andreja Brozic, Simona Kranjc, Maja Cemazar
Article
Oncology
Margareta Strojan-Flezar, Jaka Lavrencak, Mario Zganec, Primoz Strojan
RADIOLOGY AND ONCOLOGY
(2011)
Article
Biotechnology & Applied Microbiology
Lara Prosen, Sara Prijic, Branka Music, Jaka Lavrencak, Maja Cemazar, Gregor Sersa
BIOMED RESEARCH INTERNATIONAL
(2013)
Meeting Abstract
Medical Laboratory Technology
Jaka Lavrencak, Ulrika Klopcic, Veronika Kloboves Prevodnik
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2011)
Meeting Abstract
Medical Laboratory Technology
Jaka Lavrencak, Veronika Kloboves Prevodnik
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2010)
Meeting Abstract
Medical Laboratory Technology
Jaka Lavrencak, Veronika Kloboves Prevodnik, Ziva Pohar Marinsek
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2009)
Article
Cell Biology
I. Srebotnik Kirbis, M. Strojan Flezar, J. Lavrencak, Z. Pohar Marinsek